Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Bone Marrow Transplantation volume 53, pages 326–333 (2018)Cite this article

Subjects

Abstract

Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 106/kg was lower in the melphalan group. Median total yields in the melphalan, non-melphalan, and no chemotherapy groups were 5.5, 7.7, and 7.8, respectively; p < 0.001. Day-1 yields were 2.7, 3.5, and 4.0 (p = 0.0003), respectively, and median yields per collection were 2.0, 3.3, and 4.0 (p < 0.001), respectively. Similar results were observed in the sub-group analysis after plerixafor was integrated in our collection algorithm (2009). Patients in the melphalan group had higher failure rate of 9% vs. 2% each in the other two groups (p = 0.006). Impact of melphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields. Therefore, duration of melphalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, et al. Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90:1054–81.

    Article  CAS  PubMed  Google Scholar 

  2. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48:557–61.

    Article  CAS  PubMed  Google Scholar 

  3. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica. 2002;87:846–50.

    CAS  PubMed  Google Scholar 

  5. Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242–7.

    Article  CAS  PubMed  Google Scholar 

  6. Jerjis S, Croockewit S, Preijers F, Schaap N, De Witte T. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma. 2000;37:551–60.

    Article  CAS  PubMed  Google Scholar 

  7. Kazmi MA, Ahsan G, Schey SA. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma. Clin Lab Haematol. 2001;23:125–9.

    Article  CAS  PubMed  Google Scholar 

  8. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol. 1999;16:245–54.

    Article  CAS  PubMed  Google Scholar 

  9. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490–9.

    Article  CAS  PubMed  Google Scholar 

  10. de la Rubia J, Blade J, Lahuerta JJ, Ribera JM, Martinez R, Alegre A, et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica. 2006;91:621–7.

    PubMed  Google Scholar 

  11. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009;77:1655–64.

    Article  PubMed  Google Scholar 

  12. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–73.

    Article  CAS  PubMed  Google Scholar 

  13. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

    CAS  PubMed  Google Scholar 

  14. Dhakal B, Strouse C, D’Souza A, Arce-Lara C, Esselman J, Eastwood D, et al. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014;20:1926–31.

    Article  CAS  PubMed  Google Scholar 

  15. Kaul E, Shah G, Chaulagain C, Comenzo RL. Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis. Bone Marrow Transplant. 2014;49:1233.

    Article  CAS  PubMed  Google Scholar 

  16. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013;19:87–93.

    Article  CAS  PubMed  Google Scholar 

  17. JMP®, Version 12. SAS Institute Inc., Cary, NC, 1989–2007.

  18. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–42.

    Article  CAS  PubMed  Google Scholar 

  19. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111–9.

    Article  CAS  PubMed  Google Scholar 

  20. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99:743–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, et al. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer. 2016;122:2197–205

  22. Clinicaltrials.gov. A randomized open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis. 2017. https://clinicaltrials.gov/ct2/show/NCT01277016.

  23. Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121:2586–93.

    Article  CAS  PubMed  Google Scholar 

  24. Ibrahim JG, Chu H, Chen M-H. Missing data in clinical studies: issues and methods. J Clin Oncol. 2012;30:3297–303.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

    Surbhi Sidana, Nidhi Tandon, Morie A. Gertz, Angela Dispenzieri, Francis K. Buadi, Martha Q. Lacy, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Yi Lisa Hwa, Prashant Kapoor, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A. Lust, Stephen J. Russell, Steven R. Zeldenrust, S. Vincent Rajkumar, William J. Hogan & Shaji K. Kumar

  2. Division of Nephrology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

    Nelson Leung

Authors
  1. Surbhi Sidana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nidhi Tandon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morie A. Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francis K. Buadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martha Q. Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David Dingli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amie L. Fonder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Suzanne R. Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Miriam A. Hobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wilson I. Gonsalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yi Lisa Hwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Prashant Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Robert A. Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Nelson Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ronald S. Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. John A. Lust
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Stephen J. Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Steven R. Zeldenrust
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. S. Vincent Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. William J. Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Shaji K. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaji K. Kumar.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidana, S., Tandon, N., Gertz, M.A. et al. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplant 53, 326–333 (2018). https://doi.org/10.1038/s41409-017-0020-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0020-5

Search

Advanced search

Quick links